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Edited by Barry HalliwellAbstract Polyglutamine expansion in huntingtin (Htt) and the
androgen receptor (AR) causes untreatable neurodegenerative
diseases. Y-27632, a therapeutic lead, reduces Htt and AR
aggregation in cultured cells, and Htt-induced neurodegeneration
in Drosophila. Y-27632 inhibits both Rho-associated kinases
ROCK and PRK-2, making its precise intracellular target uncer-
tain. Over-expression of either kinase increases Htt and AR
aggregation. Three ROCK inhibitors (Y-27632, HA-1077, and
H-1152P), and a speciﬁc ROCK inhibitory peptide reduce poly-
glutamine protein aggregation, as does knockdown of ROCK or
PRK-2 by RNAi. RNAi also indicates that each kinase is re-
quired for the inhibitory eﬀects of Y-27632 to manifest fully.
These two actin regulatory kinases are thus involved in polyglu-
tamine aggregation, and their simultaneous inhibition may be an
important therapeutic goal.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Huntingtons disease (HD) and x-linked spinobulbar muscu-
lar atrophy (SBMA) cause devastating neurodegeneration. HD
derives from an expanded CAG codon repeat that produces an
elongated polyglutamine tract in the huntingtin (Htt) protein,
and SBMA from an elongated tract in the androgen receptor
(AR) [1,2]. There is no eﬀective therapy for any polyglutamine
disease, and the basic mechanisms that inﬂuence intracellular
polyglutamine protein aggregation and toxicity are not well
understood. Few intracellular targets amenable to mecha-
nism-based therapies have been identiﬁed. To improve quanti-
ﬁcation of intracellular aggregation, we previously developed
an intracellular aggregation assay based on ﬂuorescence reso-
nance energy transfer (FRET) [3]. In this system, the ﬁrst
127 amino acids of AR (ARN127) or the ﬁrst exon of Htt
(Htt exon 1) are fused to cyan ﬂuorescent protein (CFP) as
an energy donor, or yellow ﬂuorescent protein (YFP) as an en-
ergy acceptor and expressed in cultured cells. Even subtle
changes in aggregation may thus be quantitatively measured*Corresponding author. Address: Department of Neurology, UCSF,
GH-S572B, 600 16th Street, San Francisco, CA 94143-2280, United
States. Fax: +1 415 514 4112.
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doi:10.1016/j.febslet.2008.04.009by FRET [3]. In a screen for biologically active small molecules
that inhibit polyglutamine aggregation, we identiﬁed Y-27632.
Y-27632 reduces polyglutamine aggregation in cultured cells,
and when administered to Drosophila it reduces Htt-induced
neurodegeneration [3].
Y-27632 inhibits ROCK, a Rho-associated serine-threonine
protein kinase mainly involved in actin cytoskeleton rearrange-
ment [4–6]. Although Y-27632 has been commonly used to
study ROCK functions, like all pharmacological inhibitors it
exhibits oﬀ-target eﬀects. In vitro studies have shown that Y-
27632 also inhibits protein kinase C-related protein kinase
(PRK-2) with a similar IC50 [7]. Like ROCK, PRK-2 is an
eﬀector of the small GTPases Rho and Rac, and mediates actin
cytoskeleton rearrangements [8,9]. Thus, the molecular mecha-
nism by which Y-27632 inhibits polyglutamine aggregation is
uncertain. It is of fundamental importance to address this is-
sue, as a precise molecular target (or targets) would enable
development of a mechanism-based therapy for HD and
SBMA. We have combined chemical and genetic approaches
to test whether ROCK inhibition is the primary cause of the
inhibitory eﬀect of Y-27632 on polyglutamine aggregation.
In doing so, we have found that ROCK is only partially
responsible for the eﬀect of Y-27632 on aggregation, which is
also mediated by PRK-2. Our data suggest that these two
kinases together mediate the full anti-aggregation eﬀect of
Y-27632.2. Materials and methods
2.1. Plasmid construction
cDNAs encoding ARN127(Q65)CFP/YFP or Htt exon 1(Q72)CFP/
YFP were subcloned from p6R vector into the backbone of pECFP.N1
to drive the expression under the CMV promoter [3]. pCAG-ROCK 1
was kindly provided by Dr. Shuh Narumiya [10], and pXJ40-ROCK 2
by Dr. Thomas Leung [11]. The RBPH domain of rat ROCK 2 [11]
was PCR ampliﬁed with an amino-terminal myc-tag and cloned into
pcDNA3.1. Mutations (N1036T/K1037T) were introduced by Quick-
change.
2.2. Cell culture and transfection
HEK293 cells were cultured in DMEM containing 5% FBS and pen-
icillin/streptomycin. Transfection was performed using Plus reagent
and Lipofectamine (Invitrogen). For FRET assays, 0.6 lg plasmids
encoding ARN127(Q65)CFP/YFP or Htt exon 1(Q72)CFP/YFP were
co-transfected (at a 1:3 ratio of CFP:YFP) with or without other plas-
mids (e.g. ROCK, PRK-2, or RBPH(TT)) into 12-well dishes, grown
for 24 h, plated in 96-well black, clear-bottom plates (Costar
3603), grown for 24 h, and ﬁxed with 4% paraformaldehyde. ROCK
inhibitors (Calbiochem) were added 24 h post-transfection, and cellsblished by Elsevier B.V. All rights reserved.
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previously [3,12]. For RNAi experiments, negative control siRNA
(Santa Cruz, sc-44230), siRNAs against ROCK 1 (Santa Cruz, sc-
29473) or PRK-2 (Ambion, AM51333) were transfected for two
rounds into HEK293 cells at 75 pmol per well in a 6-well dish using
lipofectamine. ARN127(Q65)CFP/YFP and Htt exon 1(Q72)CFP/
YFP were co-transfected in the second round.
2.3. FRET measurements and calculations
FRET intensity in ﬁxed HEK293 cells was measured using a SA-
FIRE Fluorescence Plate Reader (Tecan Inc.) and calculated as de-
scribed previously [3,12]. Relative FRET/donor = [(FRET/
donor)a  (FRET/donor)b]/(FRET/donor)b, where a = cells co-trans-
fected or treated with aggregation modulators, and b = cells co-trans-
fected with control vector (pcDNA3), or untreated. For dose–response
of ROCK inhibitors, relative aggregation inhibition was calculated for
each compound by arbitrarily setting the minimum aggregation inhibi-
tion to 0 (untreated cells) and maximum to 1 (at highest tolerated drug
concentrations).Fig. 1. Inhibition of ROCK by multiple inhibitors suppresses polyglutamin
ROCK. HEK293 cells were transfected with ARN127(Q65)CFP/YFP and tr
concentrations. FRET values representing aggregation were determined on th
with one indicating maximal aggregation inhibition. All drugs dose-depen
inhibitory fragment of ROCK 2 containing the RBPH domain was muta
Pharmacologic and peptide-mediated inhibition of ROCK reduces polyglutam
ARN127(Q65)CFP/YFP (E) or Htt Exon 1(Q72)CFP/YFP (F) alone or with
(40 lM) or H-1152P (10 lM). Eﬀects were expressed as relative FRET/dono
inhibitors reduced aggregation by 25–30%. Error bars represent the S.E.M.2.4. Western blot
Rabbit polyclonal anti-ROCK 1 (sc-5560) or ROCK 2 (sc-5561)
antibodies were purchased from Santa Cruz, and used at 1:5000.
Mouse anti-PRK-2 antibody (catalog number: 610794) was purchased
from BD transduction laboratories, and used at 1:5000.3. Results
3.1. Multiple ROCK inhibitors reduce polyglutamine
aggregation
Oﬀ-target eﬀects of chemically diﬀerent kinase inhibitors are
usually distinct. Thus, if multiple inhibitors of a candidate ki-
nase produce a similar eﬀect, it is highly likely that this results
from inhibition of a speciﬁc target, rather than overlapping oﬀ-
target eﬀects. HA-1077 and H-1152P are ROCK inhibitorse aggregation. (A–C) Dose–response of pharmacologic inhibitors of
eated with (A) Y-27632, (B) HA-1077, or (C) H-1152P at the indicated
e ﬂuorescence plate reader. The relative drug responses were calculated,
dently inhibited polyglutamine aggregation. (D) A C-terminal auto-
ted at two sites (N1036T, K1037T) to abolish Rho-binding. (E, F)
ine aggregation to similar extents. HEK293 cells were transfected with
RBPH(TT), or were treated for 24 h with Y-27632 (50 lM), HA-1077
r ratios vs. untreated cells or cells transfected with an empty vector. All
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HA-1077, H-1152P is more potent and selective for ROCK
[13,14]. We tested each compound as an aggregation inhibitor
using the FRET-based aggregation assay. HEK293 cells were
transfected with ARN127(65)CFP/YFP, and relative aggrega-
tion was measured by FRET using a ﬂuorescence plate reader.
All three compounds dose-dependently inhibited polygluta-
mine aggregation (Fig. 1A–C). IC50s were approximately
5 lM for Y-27632 and HA-1077 and 0.5 lM for H-1152P, con-
sistent with the relative potencies they exhibit against ROCK
in vitro and in cells [6,14]. At maximal concentrations tolerated
by the cells, each compound inhibited ARN127(Q65) aggrega-
tion by 25–30% (Fig. 1E). Each also inhibited Htt exon 1(Q72)
aggregation dose-dependently (data not shown) and to a com-
parable extent at the highest concentrations (Fig. 1F).
As an additional test for the role of ROCK, we exploited its
auto-inhibitory mechanism to achieve more speciﬁc inhibition.
In the absence of activating stimuli (e.g. RhoA), the carboxy-
terminal RBPH (rho-binding and pleckstrin-homology) do-
main of ROCK binds and inhibits its own amino-terminal ki-
nase domain [5,6]. A mutated form of this domain
(RBPH(TT)), cannot bind RhoA [11], and speciﬁcally blocks
ROCK activity, while not aﬀecting closely related kinases that
are sensitive to inhibitors such as Y-27632 [15] (Fig. 1D).
Expression of RBPH(TT) reduced aggregation of
ARN127(Q65)CFP/YFP by up to 30% in HEK293 cells (Fig.
1E). It also inhibited Htt exon 1(Q72) aggregation to a similar
extent (Fig. 1F). Taken together, these results suggest that
ROCK regulates polyglutamine aggregation, and inhibition
of its kinase activity contributes to the anti-aggregation eﬀect
of Y-27632.
3.2. Over-expression of ROCK and PRK-2 increase
polyglutamine aggregation
ROCK has two main isoforms, ROCK 1 and ROCK 2,
which are highly conserved in sequence and function, but diﬀer
in tissue distribution. ROCK 1 is expressed in many tissues
including brain, while ROCK 2 is restricted primarily to the
brain [6,11,16]. Our preceding experiments indicated thatFig. 2. Over-expression of ROCK and PRK-2 increases polyglutamine aggreg
or Htt exon 1(Q72)CFP/YFP with an empty vector (pcDNA3), ROCK 1, RO
over-expression. (B) Eﬀects of over-expression of each protein on aggregation
with the empty vector. Over-expression of ROCK 1, ROCK 2, and PRK-2ROCK inhibition reduces polyglutamine aggregation. Thus,
we tested the eﬀects of over-expression of the two isoforms
in cultured HEK293 cells and measured aggregation using
FRET. Over-expression of ROCK 1 and ROCK 2 by transient
transfection (Fig. 2A) increased the aggregation of
ARN127(Q65)CFP/YFP by 40–60% and Htt exon
1(Q72)CFP/YFP by 35% (Fig. 2B) without changing the size
of the inclusions. Thus, ROCK activity increases polygluta-
mine aggregation, whereas its inhibition decreases aggregation.
Because Y-27632 inhibits ROCK and PRK-2 with similar
IC50s in vitro, we tested whether PRK-2 also plays a role in
polyglutamine aggregation. Over-expression of PRK-2 in cul-
tured HEK293 cells increased aggregation of
ARN127(Q65)CFP/YFP by 60% and Htt exon 1(Q72)CFP/
YFP by 40% (Fig. 2B). These data suggested that PRK-2 inhi-
bition could be an additional contributor to the eﬀect of Y-
27632 on polyglutamine aggregation.
3.3. ROCK and PRK-2 are both required for the anti-
aggregation activity of Y-27632
To test whether ROCK and PRK-2 mediate the aggrega-
tion-inhibitory eﬀect of Y-27632, we used RNA interference
to knock down the endogenous proteins. We reasoned that if
both proteins are responsible for the eﬀect of Y-27632, knock-
ing them down should eliminate the target(s) of Y-27632 and
diminish its eﬀect. We transfected HEK293 cells with a control
siRNA, or siRNAs speciﬁcally targeting ROCK 1, PRK-2, or
both. ARN127(Q65)CFP/YFP or Htt exon 1(Q72)CFP/YFP
were co-transfected with the siRNAs, followed by treatment
of cells with the vehicle control or 50 lM Y-27632. Western
blot for ROCK 1 and PRK-2 conﬁrmed the speciﬁc knock-
down of target proteins (Fig. 3A). We measured aggregation
by FRET.
We ﬁrst calculated the direct eﬀects of siRNAs on aggrega-
tion. ROCK 1 knockdown inhibited aggregation of AR by 5%
and Htt by 15%. Though modest (in particular for AR), this is
qualitatively similar to the eﬀects of pharmacologic inhibition
of ROCK. PRK-2 knockdown inhibited aggregation of AR by
24% and Htt by 34% (Fig. 3B). Simultaneous knockdown ofation. HEK293 cells were co-transfected with ARN127(Q65)CFP/YFP
CK 2, or PRK-2. (A) Western blot against each protein conﬁrmed their
were expressed as relative FRET/donor ratios vs. cells co-transfected
each increased aggregation. Error bars represent the S.E.M.
Fig. 3. RNAi knockdown of ROCK 1 and PRK-2 abolishes the inhibitory eﬀect of Y-27632 on polyglutamine aggregation. Control siRNA or
siRNAs targeting ROCK 1 or PRK-2 were transfected into HEK293 cells alone, before co-transfection with ARN127(Q65)CFP/YFP or Htt exon
1(Q72)CFP/YFP. Aggregation was measured by FRET. (A) Western blot conﬁrmed the successful knockdowns of ROCK 1 and PRK-2. (B) RNAi
knockdown of ROCK 1 and PRK-2 reduces polyglutamine aggregation. Eﬀects of ROCK 1 or PRK-2 knockdown were expressed as relative FRET/
donor ratios vs. cells transfected with the control siRNA. (C) RNAi knockdown of ROCK 1 and PRK-2 abolishes the inhibitory eﬀect of Y-27632 on
polyglutamine aggregation. Eﬀects of 50 lM Y-27632 were calculated as relative FRET/donor ratios vs. untreated cells in the presence of control,
ROCK 1, or PRK-2 siRNAs. ROCK1 or PRK-2 knockdowns each partially reduced the inhibitory eﬀect of Y-27632, and their simultaneous
knockdown abolished it, slightly increasing aggregation in response to treatment. Error bars represent the S.E.M. Statistical signiﬁcance was
calculated using the unpaired t-test (*P < 0.05, **P < 0.01, ***P < 0.005).
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Htt by 22% (Fig. 3B). The non-additive nature of these phe-
nomena likely indicate complex homeostatic mechanisms in-
duced by RNAi [17].
We next compared the anti-aggregation eﬀect of Y-27632 in
the presence or absence of RNAi knockdowns. Y-27632 inhib-
ited AR and Htt aggregation in the presence of the control siR-
NA, however, ROCK 1 and PRK-2 knockdown each
signiﬁcantly reduced its eﬀect (Fig. 3C). This suggests that each
protein is partially, but not entirely, responsible for the eﬀect
of Y-27632 on polyglutamine aggregation. Simultaneous
knockdown of ROCK 1 and PRK-2 abolished the Y-27632inhibition of AR and Htt aggregation, and engendered a slight
(<5%) increase in aggregation in the presence of the inhibitor.
This may represent unmasking of a weak, oﬀ-target eﬀect of
the compound. Taken together, these data suggest that both
ROCK and PRK-2 are targets of Y-27632, which together
mediate the full anti-aggregation eﬀect of Y-27632.4. Discussion
Our initial discovery of Y-27632 as a polyglutamine aggrega-
tion inhibitor implicated, but did not conﬁrm, the role of
J. Shao et al. / FEBS Letters 582 (2008) 1637–1642 1641ROCK in this process [3]. It also left uncertain whether other
cellular proteins might be targeted by Y-27632 to suppress
aggregation. We now observe that inhibition of ROCK by
chemically distinct inhibitors, an auto-inhibitory peptide, and
RNAi knockdown reduces polyglutamine aggregation. Con-
versely, ROCK over-expression in cultured cells increases
polyglutamine aggregation. These results directly implicate
ROCK in the regulation of polyglutamine aggregation. How-
ever, knockdown of ROCK 1 in cultured cells only partially
diminishes the eﬀect of Y-27632 on polyglutamine aggregation,
suggesting additional Y-27632 targets. Over-expression of
PRK-2, another Rho-associated kinase inhibited by Y-27632
[7], increases aggregation. Likewise, knockdown of PRK-2
suppresses polyglutamine aggregation, and partially dimin-
ishes the Y-27632 eﬀect. Simultaneous knockdown of ROCK
and PRK-2 eliminates the inhibitory eﬀect of Y-27632. Taken
together, our data imply that Y-27632 inhibits both kinases to
suppress polyglutamine aggregation.
It remains a challenge to identify and validate cellular targets
that underlie the eﬀects of bioactive compounds. Yet this could
hold the key to the development of more eﬀective therapies.
Exploiting the fact that ROCK and PRK-2 are known targets
of Y-27632, we validated their importance in regulating poly-
glutamine aggregation. Eﬀects of siRNA vs. each kinase were
not additive. This could be due to complex compensatory ef-
fects that occur in the context of chronic depletion of each pro-
tein. Likewise, the quantitative diﬀerence between
pharmacologic inhibition vs. genetic knockdown could be
due to the distinct mechanisms of these two approaches. In-
deed, this is consistent with the well-described discrepancies
between genetic knockdown and pharmacologic kinase inhibi-
tion, which can even be paradoxical within a complex intracel-
lular regulatory milieu [17]. Our data overall strongly suggest
that simultaneous ROCK and PRK-2 inhibition mediates the
intracellular anti-aggregation eﬀect of Y-27632. More potent
inhibitors of these kinases together might provide eﬀective
treatment for HD and SMBA.
In contrast to PRK-2, for which there is little pre-clinical
data, ROCK is a promising therapeutic target. It has been
implicated in multiple disease models, including hypertension,
vasospasm, renal and pulmonary ﬁbrosis (reviewed in [18]). In
the CNS, ROCK is involved in neurite retraction [19–22], and
its inhibition by Y-27632 and HA-1077 promotes axon re-
growth after spinal cord injury in experimental animals [23–
26]. Additionally, inhibition of RhoA/ROCK signaling by Y-
27632 reduces the expression of amyloid-b peptide in mouse
models of Alzheimer disease [27]. Despite its lack of selectivity
for ROCK [7], HA-1077 is currently approved for clinical use
in Japan in the treatment of primary pulmonary hypertension,
and has shown eﬃcacy in preventing vasospasm after sub-
arachnoid hemorrhage in animal models and humans [28,29].
Its IC50 in vitro against PRK-2 is only two-fold higher than
that against ROCK [7], and its eﬃcacy in vivo could result
in part from inhibition of PRK-2. However, due to reportedly
poor CNS penetration [6], in its current form it is not optimal
for treating neurodegenerative diseases such as HD.
The downstream mechanism by which ROCK and PRK-2
inhibition aﬀects polyglutamine aggregation is unknown, and
is the subject of active investigation. Both kinases are eﬀectors
of small Rho GTPases, and regulate actin cytoskeleton rear-
rangement [4,5,9,30]. Thus, the actin cytoskeleton might some-
how play a role in the regulation of polyglutamineaggregation. Indeed, recent work by others has implicated ac-
tin regulatory factors such as Arp2 and N-WASP as modula-
tors of polyglutamine aggregation in yeast and mammalian
cells [31]. Thus, further study of this pathway will yield impor-
tant insights about cellular mechanisms that inhibit polygluta-
mine protein misfolding and toxicity.
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